InvestorsHub Logo
Followers 30
Posts 2746
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Sunday, 07/10/2016 4:42:28 AM

Sunday, July 10, 2016 4:42:28 AM

Post# of 63
The two abstracts from this year's ASCO meeting - Single-Agent LV305 Induces Anti-tumor Immune And Clinical Responses In Patients With Advanced Or Metastatic Sarcoma And Other Cancers Expressing NY-ESO-1 http://www.immunedesign.com/wp-content/uploads/2016/06/LV305-ASCO-poster-2016-final-31May2016-v01.pdf and Pilot Trial Of Intratumoral G100, A Toll-like Receptor-4 (TLR4) Agonist, In Patients With Merkel Cell Carcinoma: Final Clinical Results And Immunologic Effects On The Tumor Microenvironment http://www.immunedesign.com/wp-content/uploads/2016/06/MCC-ASCO-poster-final-31May2016-v01.pdf

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.